Compare Sana Biotechnology Inc (SANA) vs Uranium Energy Corp (UEC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Sana Biotechnology Inc vs Uranium Energy Corp — how do they compare? Sana Biotechnology Inc trades at $3.17 (market cap $1.03B), while Uranium Energy Corp trades at $11.71 (market cap $5.88B). The key difference: Uranium Energy Corp is far larger — about 5.7× Sana Biotechnology Inc's market cap. Which is the better fit depends on your goals.
| SANA | UEC | |
|---|---|---|
Market Cap | $1.03B | $5.88B |
Sector | Health | Energy |
52-Week High | $5.92 | $20.14 |
52-Week Low | $2.68 | $9.04 |
Enterprise Value | $946.04M | $5.40B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SANA Biotechnology trades at $3.45, down 10.39% in the past 24 hours, reflecting bearish technical signals and negative profitability. The company reported a net loss of $244.17 million for 2025, with a price-to-book ratio of 6.68. Recent news includes investor conference presentations and a peer-reviewed publication in The New England Journal of Medicine highlighting clinical data.
Despite analyst consensus favoring a 'Buy' rating (81.82% of 11 analysts), the stock faces significant risks from negative cash flows, high losses, and potential fiduciary concerns. Upside hinges on successful clinical developments and improved financial performance, but current fundamentals suggest caution for investors.
UEC trades at $11.89, up 3.03% today, showing volatile momentum amid mixed technical signals. The stock faces fundamental challenges with negative profitability (-513.24% net margin) despite revenue of $66.84M in 2025, while analyst sentiment remains strongly bullish with 87.5% buy ratings. Recent news highlights institutional confidence, including BlackRock's $432.68M investment in August 2026, positioning UEC to benefit from nuclear energy tailwinds.
Outlook: High-risk, high-reward play on nuclear energy growth, but current financials show significant losses. Opportunities include sector tailwinds and institutional backing; risks involve persistent unprofitability and execution challenges in scaling operations. Investors should weigh speculative growth potential against fundamental weaknesses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →About Uranium Energy Corp
Uranium Energy Corp is a leading American uranium mining and exploration company, currently holding the largest resource base and licensed production capacity in the United States. Utilizing low-cost, environmentally friendly In-Situ Recovery (ISR) mining, UEC is a central player in the domestic nuclear fuel supply chain, transitioning from a resource holder to an active producer and refiner to meet the accelerating demand for carbon-free energy.
Read more on UEC →
